Therapies for Children With Autism Spectrum Disorders

Evidence Table. Therapies for children with ASD (continued)
Study
Inclusion/ Exclusion
Description Intervention
Criteria/ Population
Author industry discrimination trials using G2: 65
relationship standard error correction Mental age, months:
disclosures: procedure followed by 5 PLS-3 receptive
NR
correspondence checks communication:
Design: Error prevention group: G1: 8.4
RCT
6 subsequent teaching G2: 8.6
Note:
sessions; each session PLS-3 expressive
See related study comprised 5 conditional communication:
Carr et al. trials using error preven- G1: 8.4
2007{#462} tion procedure followed by G2: 7.6
5 correspondence checks VABS composite:
Assessments:
G1: 15
Picture Exchange G2: 15
Communication System Gender:
Groups:
NR
G1: error correction Race/ethnicity:
G2: error prevention NR
Provider:
SES:
Experimenter
Maternal education: NR
Measure of treatment Household income: NR
fidelity reported: Diagnostic approach:
No
Referral
Co-interventions held Diagnostic tool/method:
stable during treatment: Diagnosis from clinical
NR
practitioner
Concomitant therapies: Diagnostic category, n
NR
(%):
N at enrollment: Autism: 29 (100)
Total: 29
G1: 14 or 15 (NR)
G2: 14 or 15 (NR)
N at follow-up:
Total: 29
Other characteristics:
NR
Author:
Intervention:
Inclusion criteria:
Corbett et al., Tomatis Method: admi- • DSM-IV diagnosis of
2008
nistration of prepared autistic disorder
Country: auditory stimulation corroborated by the
US
recordings (2 hours/day ADOS-G and clinical
Practice filtered music, passed judgment
setting:
through Electronic Ear (for • Able to speak 1-3 words
Academic attenuation and
• Had a pointing gesture
Intervention modulation) and audio- • Tolerated wearing
setting:
vocal feedback; admini- headphones
Clinic
stered in 4 blocks, 3 Exclusion criteria:
Enrollment weeks each for duration • Previous exposure to
period:
followed by break for 18 auditory stimulation
NR
weeks. The second round treatments
Funding: (crossover design) for 18 Age, years (range):
UC Davis MIND more weeks.
Total: 5.56 (3.5-7.17)
Institute
Placebo: commercially G1: 5.25 (3.5-7.42)
Author industry produced music without G2: 5.93 (4-7.17)
relationship active microphone or Mental age:
disclosures: Electronic Ear
See baseline measures
NR
Assessments:
Gender, n (%):
Design: Stanford Binet Intelligence Male: 9 (82)
RCT, double-blind Scale, PPVT-III, EOWVT; Female: 2 (18)
crossover design context of assessments Race/ethnicity, n (%):
C-141
Baseline
Measures Outcomes
G2: 91.7 (72-100)
G1/G2: P < 0.03
Harms:
NR
Modifiers:
NR
Educational/
cognitive/
academic
attainment:
IQ mean, (range):
66.8 (52-83)
Communication/
language:
PPVT-III score,
mean ± SD:
G1: 20.83 ± 28.52
G2: 32.20 ± 25.21
EOWVT score,
mean ± SD:
G1: 16.50 ± 21.11
G2: 25.20 ± 19.82
Educational/
cognitive/
academic
attainment:
IQ, mean, (range):
62.45 (44-84)
Communication/
language:
PPVT-III score,
mean ± SD:
Mid-treatment:
G1: 20 ± 25.76
G2: 40.2 ± 26.69
Post-treatment:
G1: 22.83 ± 29.36
G2: 47.2 ± 24.45
ANOVA: group
(P = NS), time
(P = 0.03), time Х
group (P = 0.08)
EOWVT score,
mean ± SD:
Mid-treatment:
G1: 18 ± 18.73